A Cholesterol Lowering Therapy of Focused Power Ultrasound Mediated Perirenal Fat Ablation

Dyslipidemias Clinical Trial

— CONCISE  

Official title:

Non-invasive Focused Power Ultrasound Mediated Inferior Perirenal Fat Ablation for Lowering Serum Cholesterol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04223557
• Other study ID #: 2019-SR-388
• Status: Completed
• Phase: N/A
• Start date: May 30, 2020
• Est. completion date: December 31, 2021

Study information

• Verified date: July 2023
• Source: The First Affiliated Hospital with Nanjing Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about focused power ultrasound (FPU)-mediated perirenal fat (PRF) ablation for lowering serum cholesterol levels. The main questions it aims to answer are:

What is the efficacy, safety, and tolerability of focused power ultrasound (FPU)-mediated perirenal fat ablation for lowering low-density lipoprotein cholesterol (LDL-C) levels? Participants will randomly receive PRF ablation or sham treatment, and undergo follow-up at 24 hours, 1 month, and 3 months post-procedure.

Description:

This study aims to evaluate and validate the efficacy and safety of the therapeutic approach of PRF ablation-executed by an externally delivered, completely non-invasive FPU-on serum cholesterol levels in patients with dyslipidaemia, with a low-to-moderate 10-year overall risk of ASCVD.

This is an investigator-initiated, single site, randomised, double-blinded, sham-controlled clinical trial. Further eligibility assessment will be performed at the secondary screening, which has the same design as the baseline examination. Subjects taking lipid-lowering drugs before the recruitment are permitted to enter the secondary screening after a 4-week washout period, to allow for sufficient elimination. Eighty-four eligible participants will be randomly assigned to either the FPU treatment group or the sham-treatment group, at a ratio of 2:1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: December 31, 2021
• Est. primary completion date: July 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Males and Females aged 18-70 years old.

2. Each side of caudal perirenal fat volume >8000mm3(measured by ultrasound).

3. Low and medium-risk of arteriosclerotic cardiovascular disease (ASCVD) with 3.4 = LDL-C < 4.9 mmol/L or 5.2 = TC < 7.2 mmol/L, as defined by the Chinese guidelines for the management of dyslipidemia in adults(revised edition 2016).

4. Participants should be willing to sign the informed consent form of the study.

Exclusion Criteria:

1. Familial hyperlipidemia.

2. Participants are taking cholesterol metabolism related drugs (e.g. fibrate drugs, thiazide diuretics, glucocorticoid, para-amino salicylic acid, colchicine, thyroid hormone, thyroid preparation, hypoglycemic, heparin, new oral anticoagulant, chlortetracycline, kanamycin, neomycin).

3. Participants are unwilling to stop taking statins.

4. Presence of history of hypertension and at least 2 of the following risk factors:

• History of smoking (more than 10 years and more than 10 cigarettes per day).

• Male = 45 years old, female = 55 years old.

• HDL-C=1 mmol/L.

5. Presence of clinical documented atherosclerotic cardiovascular diseases (including acute coronary syndrome, stable angina, coronary revascularization, ischemic cardiomyopathy, stroke, transient cerebral ischemia and peripheral atherosclerosis disease defined as stenosis =50% or complex plaques of lower limb arteries, renal arteries, carotid arteries and other peripheral arteries).

6. Presence of cardiovascular diseases(e.g. all types of atrial fibrillation; severe structural heart disease including severe pulmonary hypertension resulting from severe aortic or ventricular septal defect, complicated anomaly and severe valvular disease; second degree or above heart block).

7. Presence of previous surgery of kidney or pararenal tissue.

8. Presence of endocrine-related diseases(e.g. Diabetes, Cushing syndrome, thyroidectomy or thyroid dysfunction in need of drug treatment, primary aldosteronism, Hypofunction of adrenal cortex, Polycystic Ovary Syndrome, Hyperparathyroidism, Insulin tumor, Zollinger-Ellison syndrome).

9. Presence of autoimmune diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, scleroderma, ulcerative colitis, dermatomyositis, pemphigus, mixed connective tissue disease, sarcoidosis, Takayasu Arteritis).

10. Presence of severe hematologic diseases (e.g. leukemia, lymphoma, aplastic anemia, autoimmune hemolytic anemia, multiple myeloma, Primary Immune Thrombocytopenia, thrombotic thrombocytopenic Purpura, abnormal coagulation).

11. Presence of infectious diseases (e.g. Hepatitis, tuberculosis, AIDS, syphilis, malaria, measles).

12. Presence of parasitic diseases.

13. Presence of significant liver dysfunction (ALT or AST elevation greater than 2 times normal upper limit or other evidence of liver injury).

14. Presence of significant renal dysfunction (GFR< 90 mL / min / 1.73 m2 or other evidence of renal injury).

15. Presence of urinary calculi and/or hematuria (gross hematuria or occult blood positive).

16. Presence of skin infection at the waist.

17. Presence of active malignancy.

18. Pregnant women or in suckling period or planning for pregnancy in trial period.

19. Participants are unwilling to sign an informed consent form.

20. Participants are unable or unwilling to complete follow-up evaluations.

Related Conditions & MeSH terms

• Dyslipidemias
• Obesity, Abdominal
• Ultrasound Therapy
• Visceral Obesity

Intervention

Device:
• focused power ultrasound treatment
Patients will be placed in the lateral decubitus position and receive treatment with sequential bilateral PRF ablation. Before the treatment, a professional sonographer will be responsible for the length, thickness, and width of PRF sac measurement and localisation, and utilise the ultrasonic diagnostic transducer to delineate the targeted region. The treatment will launch layer-by-layer. After confirming accurate localization of the treatment, layer-by-layer PRF ablation will be performed on the patients. The device generates and delivers a pattern of conic-shaped ultrasound energy to the PRF sac noninvasively. The treatment of FPU-mediated PRF ablation will be implemented once.
• Sham treatment
Participants will receive the same procedure as those in the FPU treatment including PRF ultrasonic measurement and localization and focused ultrasound treatment parameters setting, except that no energy will be delivered to the PRF.

Locations

Country	Name	City	State
China	JiangSu Province Hospital / The First Affiliated Hospital of Nanjing Medical University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The difference in low-density lipoprotein cholesterol (LDL-C) levels between the FPU-treatment and sham treatment groups from baseline to 3 months post-procedure	The difference in LDL-C levels between the FPU-treatment and sham treatment groups from baseline to 3 months post-procedure.	Day 0 (baseline) to 3-month (end of follow-up)
Primary	Incidence of all-cause deaths and serious adverse events	Serious adverse events including acute liver failure, acute renal failure, acute intestinal perforation, severe embolic events and etc.	Day 0 (baseline) to 3-month (end of follow-up)
Secondary	The differences between the groups in blood lipid profiles (total cholesterol(TC), triglycerides(TG), and high-density lipoprotein cholesterol(HDL-C)) from baseline to 3 months post-procedure.	The differences between the groups in blood lipid profiles (total cholesterol(TC), triglycerides(TG), and high-density lipoprotein cholesterol(HDL-C)) from baseline to 3 months post-procedure.	Day 0 (baseline) to 3-month (end of follow-up)
Secondary	Incidence of other adverse events	Other adverse events including liver dysfunction, renal dysfunction, etc. at 3 months post-procedure. The following are the safety assessments: General physical examination and vital signs.; Routine blood and urine tests: C-reactive protein (CRP), ALT, AST, urea nitrogen (BUN), creatinine (Cr), and glycosylated haemoglobin (HbAlc).; Image examinations: electrocardiogram (ECG), renal and renal artery ultrasound, and mid-abdomen routine computed tomography (MAR-CT).; AEs (including ALT or AST = 3 times the upper limit of normal, Cr = 1.5 times the upper limit of normal, and other AEs).	Day 0 (baseline) to 3-month (end of follow-up)